There are currently 147 active clinical trials seeking participants for Melanoma research studies. The states with the highest number of trials for Autism participants are California, Texas, Florida and Pennsylvania.
A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
NCT04567706
Recruiting
This study collects and stores blood and tumor samples from patients with malignant melanoma and healthy individuals. The purpose of this study is to gain a better understanding of the causes of melanoma and how melanoma tumors behave. Storing blood and tumor samples for future research may lead to new discoveries that may ultimately help with diagnosing or treating this disease.
Gender:
All
Ages:
All
Trial Updated:
03/07/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Melanoma
Register for Updates
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT05136196
Recruiting
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona +178 locations
Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Lip and Oral Cavity Squamous Cell Carcinoma, Melanoma, Oropharyngeal Squamous Cell Carcinoma
Register for Updates
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577
Recruiting
The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Highlands Oncology Group ( Site 1943), Springdale, Arkansas +128 locations
Conditions: Melanoma
Register for Updates
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT04291105
Recruiting
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Mayo Clinical, Phoenix, Arizona +25 locations
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Register for Updates
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
NCT04594187
Recruiting
This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without completion lymph node dissection. Prior studies of patients with more advanced melanoma have shown nodal radiation therapy can decrease the risk of nodal recurrence but it is not known if this same benefit will be seen in patients with high risk sentinel lymph node positive di... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Baptist - MD Anderson Cancer Center, Jacksonville, Florida +2 locations
Conditions: Melanoma
Register for Updates
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
NCT04866810
Recruiting
Background: The gut microbiome is made up microorganisms. These include the good and bad bacteria that live in the digestive tract. Changes in the gut microbiome have been linked to the development of cancer. Researchers want to learn more about the effects of modulating the microbiome with diet and exercise. Objective: To see if nutritional intake and physical activity change the gut microbiome in people with melanoma. Eligibility: Adults age 18 and older with previously untreated melanoma... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/20/2024
Locations: Loma Linda University, Loma Linda, California +1 locations
Conditions: Melanoma
Register for Updates
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
NCT04305054
Recruiting
Substudy 02B is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02B is to evaluate the safety and efficacy of investigational treatment arms in participants with 1L advanced melanoma and to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/pembrolizumab monotherapy. Arm 1: Pembrolizumab + Vibostolimab was add... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/19/2024
Locations: The Angeles Clinic and Research Institute ( Site 2009), Los Angeles, California +54 locations
Conditions: Melanoma
Register for Updates
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05581004
Recruiting
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, urothelial carcinoma (UC), clear... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Stanford University', San Francisco, California +32 locations
Conditions: Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Register for Updates
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
NCT05812027
Recruiting
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if s... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: HonorHealth Research and Innovation Institute, Scottsdale, Arizona +13 locations
Conditions: Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, Melanoma, Ovarian Cancer, HPV16 Related Cancers
Register for Updates
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782
Recruiting
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab (MK-3475A) administered subcutaneously (SC) over pembrolizumab (MK-3475) administered intravenously (IV) in participants with multiple tumor types. There will be no hypothesis testing in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Alaska Oncology and Hematology ( Site 0121), Anchorage, Alaska +34 locations
Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Register for Updates
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
NCT04609566
Recruiting
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Arizona Oncology Associates, PC - HOPE, Tucson, Arizona +32 locations
Conditions: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Register for Updates
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291
Recruiting
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab. The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at hi... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
04/19/2024
Locations: University of California San Diego, La Jolla, California +195 locations
Conditions: Melanoma
Register for Updates